Jaguar Health Inc
JAGX1.680USD
-0.170-9.19%
收盤 11/04, 16:00（美東）報價延遲15分鐘
2.57M總市值
虧損本益比TTM
關於 Jaguar Health Inc 公司
Jaguar Health, Inc. 是一家商業階段的製藥公司。該公司專注於開發可持續地從雨林地區植物中提取的新型專利處方藥，用於治療患有胃腸道不適的人和動物。該公司通過兩個部門運營：人類健康和動物健康。動物健康部門專注於開發和商業化伴侶動物和生產動物的處方和非處方產品。人類健康部門專注於開發和商業化人類產品以及持續商業化 Mytesi，Mytesi 用於緩解接受抗逆轉錄病毒治療的人類免疫缺陷病毒 (HIV)/獲得性免疫缺陷綜合徵 (AIDS) 成人患者的非感染性腹瀉症狀。Canalevia-CA1 用於治療狗的化療引起的腹瀉 (CID)。其子公司 Napo Pharmaceuticals, Inc. 專注於開發和商業化人類處方藥。
Jaguar Health Inc簡介
公司代碼JAGX
公司名稱Jaguar Health Inc
上市日期May 13, 2015
CEOMs. Lisa A. Conte
員工數量49
證券類型Ordinary Share
年結日May 13
公司地址200 Pine Street Suite 400
城市SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94104
電話14153718300
網址https://jaguar.health/
公司代碼JAGX
上市日期May 13, 2015
CEOMs. Lisa A. Conte
Jaguar Health Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Pravin R. Chaturvedi, Ph.D.
Dr. Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
137.00
+98.55%
Mr. Jonathan S. Wolin
Mr. Jonathan S. Wolin
Chief of Staff, General Counsel, Chief Compliance Officer
Chief of Staff, General Counsel, Chief Compliance Officer
132.00
+100.00%
Mr. Jonathan B. Siegel
Mr. Jonathan B. Siegel
Independent Director
Independent Director
45.00
--
Mr. John J. Micek, III
Mr. John J. Micek, III
Independent Director
Independent Director
--
--
Ms. Carol R. Lizak
Ms. Carol R. Lizak
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven R. King, Ph.D.
Dr. Steven R. King, Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
--
--
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Ian Wendt
Mr. Ian Wendt
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Lisa A. Conte
Ms. Lisa A. Conte
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. James J. Bochnowski
Mr. James J. Bochnowski
Independent Chairman of the Board
Independent Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Pravin R. Chaturvedi, Ph.D.
Dr. Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
137.00
+98.55%
Mr. Jonathan S. Wolin
Mr. Jonathan S. Wolin
Chief of Staff, General Counsel, Chief Compliance Officer
Chief of Staff, General Counsel, Chief Compliance Officer
132.00
+100.00%
Mr. Jonathan B. Siegel
Mr. Jonathan B. Siegel
Independent Director
Independent Director
45.00
--
Mr. John J. Micek, III
Mr. John J. Micek, III
Independent Director
Independent Director
--
--
Ms. Carol R. Lizak
Ms. Carol R. Lizak
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven R. King, Ph.D.
Dr. Steven R. King, Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月3日 週三
更新時間: 9月3日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Lincoln Alternative Strategies LLC
17.02%
Streeterville Capital LLC
1.29%
Iliad Research & Trading, L.P.
0.90%
Intracoastal Capital, L.L.C.
0.77%
UBS Financial Services, Inc.
0.58%
其他
79.43%
持股股東
持股股東
佔比
Lincoln Alternative Strategies LLC
17.02%
Streeterville Capital LLC
1.29%
Iliad Research & Trading, L.P.
0.90%
Intracoastal Capital, L.L.C.
0.77%
UBS Financial Services, Inc.
0.58%
其他
79.43%
股東類型
持股股東
佔比
Corporation
19.98%
Investment Advisor
0.60%
Hedge Fund
0.07%
Individual Investor
0.05%
其他
79.29%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
32
13.68K
0.68%
-87.94K
2025Q2
46
243.00K
13.10%
+147.33K
2025Q1
51
102.25K
9.10%
+15.99K
2024Q4
58
1.15M
16.97%
+379.12K
2024Q3
61
1.40M
25.15%
+578.82K
2024Q2
62
807.73K
26.56%
+336.48K
2024Q1
65
210.88K
23.56%
+139.83K
2023Q4
66
157.05K
30.73%
+119.23K
2023Q3
72
88.91K
41.12%
+74.12K
2023Q2
76
63.74K
33.22%
+52.52K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lincoln Alternative Strategies LLC
600.00K
17.02%
+600.00K
--
Aug 28, 2025
Streeterville Capital LLC
45.48K
1.29%
+35.18K
+341.53%
May 08, 2025
Iliad Research & Trading, L.P.
31.83K
0.9%
+16.08K
+102.12%
Jul 18, 2024
Intracoastal Capital, L.L.C.
27.00K
0.77%
+27.00K
--
May 27, 2025
UBS Financial Services, Inc.
11.17K
0.58%
+6.86K
+158.93%
Jun 30, 2025
Tower Research Capital LLC
1.59K
0.07%
+1.59K
--
Jun 30, 2025
RBC Dominion Securities, Inc.
702.00
0.02%
+702.00
--
Mar 31, 2025
Conte (Lisa A.)
261.00
0.02%
+128.00
+96.24%
Jul 08, 2025
King (Steven R. Ph.D.)
107.00
0.01%
+53.00
+98.15%
Jul 08, 2025
SBI Securities Co., Ltd.
200.00
0.01%
+180.00
+900.00%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
公告日期
類型
比率
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
Mar 18, 2025
Merger
25→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
May 20, 2024
Merger
60→1
Jan 20, 2023
Merger
75→1
Jan 20, 2023
Merger
75→1
查看更多
